Tonkin AM - Search Results

1

Changes in plasma lipids predict pravastatin efficacy in secondary prevention.

Jayawardana KS, Mundra PA, Giles C, Barlow CK, Nestel PJ, Barnes EH, Kirby A, Thompson P, Sullivan DR, Alshehry ZH, Mellett NA, Huynh K, McConville MJ, Zoungas S, Hillis GS, Chalmers J, Woodward M, Marschner IC, Wong G, Kingwell BA, Simes J, Tonkin AM, Meikle PJ; LIPID Study Investigators. Jayawardana KS, et al. Among authors: tonkin am. JCI Insight. 2019 Jul 11;4(13):e128438. doi: 10.1172/jci.insight.128438. eCollection 2019 Jul 11. JCI Insight. 2019. PMID: 31292301 Free PMC article. Clinical Trial.

2

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators. Simes RJ, et al. Circulation. 2002 Mar 12;105(10):1162-9. doi: 10.1161/hc1002.105136. Circulation. 2002. PMID: 11889008

3

Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?

Glasziou PP, Eckermann SD, Mulray SE, Simes RJ, Martin AJ, Kirby AC, Hall JP, Caleo S, White HD, Tonkin AM. Glasziou PP, et al. Among authors: tonkin am. Med J Aust. 2002 Oct 21;177(8):428-34. doi: 10.5694/j.1326-5377.2002.tb04883.x. Med J Aust. 2002. PMID: 12381252

4

Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin.

West MJ, White HD, Simes RJ, Kirby A, Watson JD, Anderson NE, Hankey GJ, Wonders S, Hunt D, Tonkin AM. West MJ, et al. Among authors: tonkin am. J Hypertens. 2002 Dec;20(12):2513-7. doi: 10.1097/00004872-200212000-00032. J Hypertens. 2002. PMID: 12473877 Clinical Trial.

5

Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.

Hague W, Forder P, Simes J, Hunt D, Tonkin A; LIPID Investigators. Hague W, et al. Am Heart J. 2003 Apr;145(4):643-51. doi: 10.1067/mhj.2003.1. Am Heart J. 2003. PMID: 12679760 Clinical Trial.

6

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group. Keech A, et al. Diabetes Care. 2003 Oct;26(10):2713-21. doi: 10.2337/diacare.26.10.2713. Diabetes Care. 2003. PMID: 14514569 Clinical Trial.

7

Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study.

Magliano D, Liew D, Pater H, Kirby A, Hunt D, Simes J, Sundararajan V, Tonkin A. Magliano D, et al. Aust N Z J Public Health. 2003 Dec;27(6):649-53. doi: 10.1111/j.1467-842x.2003.tb00615.x. Aust N Z J Public Health. 2003. PMID: 14723416 Free article.

8

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.

Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A; LIPID Study Investigators. Colquhoun D, et al. Eur Heart J. 2004 May;25(9):771-7. doi: 10.1016/j.ehj.2004.03.013. Eur Heart J. 2004. PMID: 15120888 Clinical Trial.

9

Effect of pravastatin on cardiovascular events in people with chronic kidney disease.

Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M. Tonelli M, et al. Circulation. 2004 Sep 21;110(12):1557-63. doi: 10.1161/01.CIR.0000143892.84582.60. Epub 2004 Sep 13. Circulation. 2004. PMID: 15364796 Review.

10

White blood cell count predicts reduction in coronary heart disease mortality with pravastatin.

Stewart RA, White HD, Kirby AC, Heritier SR, Simes RJ, Nestel PJ, West MJ, Colquhoun DM, Tonkin AM; Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Investigators. Stewart RA, et al. Among authors: tonkin am. Circulation. 2005 Apr 12;111(14):1756-62. doi: 10.1161/01.CIR.0000160924.73417.26. Epub 2005 Apr 4. Circulation. 2005. PMID: 15809366 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

368 results

Search Page